RegeneRx Seeks Cosmeceutical Partners While Developing Drugs
This article was originally published in The Rose Sheet
Executive Summary
Cash-strapped Maryland biotech firm RegeneRx is in talks with global cosmetics firms to develop products from its drug candidate molecule T?4 and hopes to see revenue from cosmeceuticals by 2010
You may also be interested in...
Lauder/Allergan Marriage Delivers Clinique Medical For Cosmetic Procedures
The Estee Lauder Companies has joined with pharmaceutical firm Allergan to launch Clinique Medical, a line of skin-care products designed to prepare skin for non-surgical cosmetic procedures and assist in the healing process, the firm says Oct. 15
Elizabeth Arden To Co-Market Prevage Cream Under Allergan Deal
Elizabeth Arden is making its foray into the cosmeceutical skin care market through an exclusive co-marketing agreement with Prevage manufacturer Allergan
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.